Medication info
Diabex XR Sustained Release Tablet 500 mg (Metformin Hydrochloride)

Diabex XR Sustained Release Tablet 500 mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceuticals
Appearance
White to off-white, double-convex, round sustained release tablets
Packaging
60 tablets (15 tablets/PTP) × 4
Approval status
Active

MFDS item code 200511904 · Approved 2005.09.30 · Insurance code 641600360

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on the drug’s efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week, up to a maximum of 2000mg per day with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At the start of treatment and when adjusting the dose, fasting blood glucose should be measured to assess the response to this drug and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured at approximately 3-month intervals. - The goal of treatment with this drug, when given as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this drug must be discontinued immediately.

Ingredients

Importer
Daewoong Pharmaceuticals

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used for the treatment of adult patients with type 2 diabetes who do not achieve sufficient blood sugar control with diet and exercise alone, especially for overweight diabetic patients. It helps to effectively control blood sugar either when used alone or in combination with other oral hypoglycemic agents or insulin.

How to take

Adult dose

The dose should be determined individually based on the drug’s efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase it by 500mg each week, up to a maximum of 2000mg per day with the evening meal. If glycemic control is not achieved with a maximum once-daily dose of 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this product is the same as the daily dose of immediate-release metformin tablets. Switching to this product is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At the start of treatment and when adjusting the dose, fasting blood glucose should be measured to assess the response to this drug and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured at approximately 3-month intervals. - The goal of treatment with this drug, when given as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this drug must be discontinued immediately.

Precautions

This medication can rarely cause serious lactic acidosis, so caution is required. There is a risk of hypoglycemia when used with other diabetes medications, so care must be taken. This medication should not be used in patients with moderate to severe renal impairment or conditions such as dehydration, severe infections, and acute myocardial infarction. Patients with acute heart failure or those scheduled for examinations using radiographic iodine contrast agents should also not be administered this medication. It should not be administered to patients with allergies to its ingredients, type 1 diabetes, or severe metabolic acidosis. In cases of severe infections, trauma, or before and after surgery, this medication should be temporarily discontinued and resumed only when kidney function is normal. Patients with poor nutritional status, liver dysfunction, respiratory failure, or excessive alcohol consumption require caution when using this medication. Should not be initiated in pregnant women with placental insufficiency or at risk for preeclampsia. Patients with irregular meals, intense exercise, or taking interacting medications should use this medication cautiously due to the risk of hypoglycemia and lactic acidosis. This medication may cause gastrointestinal distress, vitamin B12 deficiency, taste disturbance, and other side effects; if symptoms occur, consult a healthcare professional. Regular kidney function tests are necessary to monitor renal status, and if kidney function deteriorates, administration should be discontinued. Alcohol consumption can affect lactate metabolism and increase risks, so it is advisable to avoid it. This medication may interact with other drugs, so blood sugar and conditions should be closely monitored when used in combination. If blood sugar control is needed during pregnancy, it may be used in combination with insulin at the physician's discretion, but fetal development monitoring is necessary. During breastfeeding, this medication is excreted in breast milk, so careful consideration of whether to breastfeed and whether to discontinue medication therapy is required. Elderly patients are at higher risk for decreased kidney function; treatment should start at the minimum dose and kidney function should be checked regularly. In the event of overdose, blood dialysis can remove the drug, so immediate medical attention is necessary. Do not crush or chew the tablets, and it is normal for the tablet coating to appear in the stool. During the use of this medication, adherence to dietary therapy, regular exercise, and consistent monitoring of blood sugar and kidney function tests is essential.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. Additionally, it is recommended to store it at room temperature between 1°C and 30°C, away from extreme heat or cold.

Appearance and packaging

Appearance

White to off-white, double-convex, round sustained release tablets

Package unit

60 tablets (15 tablets/PTP) × 4

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.